Dinaciclib as an effective pan-cyclin dependent kinase inhibitor in platinum resistant ovarian cancer

BACKGROUND: Ovarian cancer (OC) is amongst the most lethal of common cancers in women. Lacking in specific symptoms in the early stages, OC is predominantly diagnosed late when the disease has undergone metastatic spread and chemotherapy is relied on to prolong life. Platinum-based therapies are pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Howard, David, James, David, Garcia-Parra, Jezabel, Pan-Castillo, Belen, Worthington, Jenny, Williams, Nicole, Coombes, Zoe, Rees, Sophie Colleen, Lutchman-Singh, Kerryn, Francis, Lewis W., Rees, Paul, Margarit, Lavinia, Conlan, R. Steven, Gonzalez, Deyarina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732436/
https://www.ncbi.nlm.nih.gov/pubmed/36505806
http://dx.doi.org/10.3389/fonc.2022.1014280

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732436/
https://www.ncbi.nlm.nih.gov/pubmed/36505806
http://dx.doi.org/10.3389/fonc.2022.1014280

Ejemplares similares